TikTok Moment For BeiGene, Junshi As FDA Looks At China PD-1s
At Least One To Score Approval?
Amid deepening bilateral decoupling and geopolitical tensions, the US regulatory agency is sending field inspectors to China for the first time in three years as it moves forward in reviewing and potentially approving the first 'Made In China' immuno-oncology drugs.
You may also be interested in...
Dr Reddy’s CEO: We’re In ‘Great Dialogue’ With The Innovation Industry In China
Dr Reddy’s is collaborating with innovator firms in China, Israel and the US largely in areas of unmet need, propelling its “Horizon-2” strategy that encompasses segments like biologics and cell and gene therapy, digital services and immuno-oncology NCEs, among others.
Lilly Unlucky? Lilly Leads Big Pharma In US FDA Complete Response Letters
Clinical concerns outweigh quality issues in big pharma CRLs, a Pink Sheet analysis finds, making mirikizumab – the fourth new product candidate sponsored by Lilly to receive a CRL since 2021 – even more of an outlier: it was turned back by FDA because of manufacturing concerns.
BeiGene’s Tislelizumab Delivers With OS Data In Broad Gastric Cancer Population
The PD-L1 inhibitor partnered with Novartis improved overall survival in combination with chemotherapy in gastric cancer patients regardless of PD-L1 status.